Considerations for the Management of Overactive Bladder in Long-Term Care

This clinical brief is supported by Sumitomo Pharma America.

This information is intended solely for payer and formulary decision makers and is provided for informational purposes regarding reimbursement and healthcare decision-making. This material is non-promotional and should not be distributed or used for promotional purposes.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Considerations for the Management of Overactive Bladder in Long-Term Care

Trending on AJMC

Lipoprotein(a): An FAQ on Awareness, Risk, and Screening Gaps

$20 Billion National Strategy Aims to Close the Women's Health Gap

Smartwatch Study Links Midlife to Rising Nighttime Awakenings in Women

Gene Therapy for Wet AMD Near an Inflection Point: Arshad Khanani, MD

FDA Approves Gwyn Lo, a New Low-Dose Contraceptive Patch

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

Considerations for the Management of Overactive Bladder in Long-Term Care

Trending on AJMC

Lipoprotein(a): An FAQ on Awareness, Risk, and Screening Gaps

$20 Billion National Strategy Aims to Close the Women's Health Gap

Smartwatch Study Links Midlife to Rising Nighttime Awakenings in Women

Gene Therapy for Wet AMD Near an Inflection Point: Arshad Khanani, MD

FDA Approves Gwyn Lo, a New Low-Dose Contraceptive Patch